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We read with great interest the editorial comment of Giannarini and Autorino referring to our 
article published in this issue of the "Platinum Journal" [1,2]. The authors are to be 
congratulated for their summary of the current knowledge about medical expulsive therapy 
(MET) in patients with distal ureteral stones. 
However, we would like to bring the attention of the two authors and of the readers of 
European Urology to a clinical case scenario and leave theoretical assumptions aside. We 
invite the readers to remember their last patient who presented to the emergency department 
with acute flank pain due to a distal ureteral stone. Let’s presume he is a 39-year-old healthy 
man without a previous history of urinary stone disease. First of all, the resident on call has to 
decide what sort of imaging the patient should obtain to confirm the suspected diagnosis. 
Hopefully, he will decide for the gold standard, i.e. non-contrast enhanced computed 
tomography (CT) [3, 4]. But what stone size is the resident about to expect and measure on 
the CT scan? Not surprisingly, like the majority of patients (85-93%) presenting with distal 
ureteral stones this man most probably will have a stone of less than 7 mm in size [5, 6]. 
Accordingly, he will have a fairly high probability of a spontaneous stone passage within 3 to 
4 weeks. Nonetheless, the probability that a stone up to 7 mm in size will not pass 
spontaneously is still 15-55% [7]. Furthermore, it is not possible to reliably predict the time of 
stone passage and the number and intensity of painful episodes until stone expulsion [6]. 
Certainly, the well trained resident will remember that MET is a treatment option for this 
patient, who, thus, is being at risk to receive an off-label alpha-blocker treatment .  
We constantly teach our residents to follow evidence-based guidelines. However, after having 
read the latest guidelines on the management of distal ureteral stones facing this frequently 
encountered clinical situation the resident astonishingly understands that the available 
evidence to support MET with tamsulosin in this setting is scarce [7, 8].  
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What do we learn from this case vignette? Stones in the distal ureter are rarely bigger than 7 
mm. The standard imaging modality is an unenhanced CT scan. Although MET has gained 
wide popularity not only among urologists but also among emergency physicians, level I 
evidence providing efficacy of MET in this setting is scarce or until recently has even been 
absent. 
In this perspective, our trial published in this month’s issue of European Urology focused on 
the most frequent clinical case scenarios encountered– i.e. patients with distal ureteral stones 
up to 7 mm in size. It has been an unanswered question whether MET with tamsulosin 
provides any benefit for patients in this setting although it has already been introduced into 
routine clinical practice [9]. Thus, we present for the first time high-level evidence from a 
randomized, double-blind and placebo-controlled trial evaluating the efficacy of MET with 
tamsulosin. Moreover, in our trial, assessment of initial and final stone status has been 
performed using the gold standard technique i.e. unenhanced CT. In many of the previously 
published studies with flaws in randomization and blinding, this imaging technique was not 
used for stone size and endpoint-assessment. 
Therefore, we do not understand why Giannarini and Autorino argue that our study design is 
not entirely correct. The target study population was well chosen and the methods we applied 
withstand criticism in terms of the chosen imaging modality, statistical methods, and 
reporting of study design and results in accordance with the CONSORT criteria [10]. As a 
matter of fact, we did not (and did not want to) include patients harbouring “medium to large” 
sized stones. Several authors argue that the efficacy of MET may increase or be more clearly 
apparent in patients with larger stones [11]. Again, so far, this argument has not been 
evaluated properly. We wonder how patients with stones bigger than 7 mm would appreciate 
it to be put on a MET study protocol if they are appropriately informed about the success rate 
of alternative treatment options and their risk not to pass the stone if allocated to the placebo 
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arm. These patients are expecting a chance of passing their stone spontaneously with a 
probability of 27-47% [5, 7]. Given an optimistic estimation of MET efficacy in this setting, 
spontaneous stone expulsion may be increased with MET by 20%. This means that still about 
40-60% of patients are at risk for complications and dreaded colics and finally will require 
interventional treatment. We doubt it that in this setting MET will still prove to be cost 
effective [12]. Having said this, at least in our patient population deferring therapy for stones 
more than 7 mm in size is not easy to accomplish. Additionally, to include patients in a MET 
trial 3-4 weeks after onset of symptoms as proposed by Giannarini and Autorino to rule out 
confounding effects of spontaneous stone passage is difficult to imagine being feasible, at 
least in our patient population.  
We leave the decision to the readers of European Urology if they still want to continue with 
MET using tamsulosin because of the observed analgesic effect and faster time to stone 
expulsion or if they abandon tamsulosin and continue to treat their patients with officially 
approved analgesics or e.g. straightforward with highly successful ureteroscopy. 
After all, in 2007 the distinguished joint AUA-EAU guideline panel for the management of 
ureteral stones recommended for the future to conduct double-blinded randomized controlled 
trials to assess MET [7]. The jury is still open for MET in stones bigger than 7 mm. However, 
for stones up to 7 mm our trial provides for the first time level I evidence for MET with 
tamsulosin and thus is not a step back in MET but definitively a step forward.  
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